GlassScriptPhysician profile
Sandeep Rajan
NPI 1396852273
$464,885.06
in general payments reported to CMS, 2019-2025
53 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170K · 2020: $53K · 2021: $32K · 2022: $84K · 2023: $35K · 2024: $62K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Travel and Lodging: $13K · Consulting Fee: $8,562 · Food and Beverage: $3,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,765.39 |
| Travel and Lodging | $13,216.41 |
| Consulting Fee | $8,562.00 |
| Food and Beverage | $3,893.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $173,037.65 | 2019-2025 | Novoseven, Alhemo |
| Alexion Pharmaceuticals, INC. | $96,864.58 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $79,245.06 | 2019-2025 | |
| Bioverativ Therapeutics INC. | $59,755.33 | 2019-2021 | |
| Shire North American Group INC | $23,759.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13,612.36 | 2020-2025 | Vpriv |
| Biomarin Pharmaceutical INC. | $5,543.89 | 2019 | |
| Apellis Pharmaceuticals, INC. | $3,985.00 | 2023 | Empaveli |
| Octapharma USA, INC. | $2,512.75 | 2020 | |
| Genentech USA, INC. | $1,788.11 | 2020-2024 | Lunsumio, Polivy, Columvi |
| Bayer Healthcare Pharmaceuticals INC. | $1,280.94 | 2020-2025 | |
| Agios Pharmaceuticals, INC. | $857.97 | 2022-2024 | Pyrukynd |
| Celgene Corporation | $294.41 | 2024-2025 | Reblozyl |
| Pfizer INC. | $204.45 | 2021-2025 | |
| Eisai INC. | $197.36 | 2024-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $194.42 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $153.31 | 2024-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $152.48 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Glaxosmithkline, LLC. | $117.85 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $115.45 | 2022-2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $94.68 | 2025 | Erleada, Balversa, Akeega |
| Novartis Pharmaceuticals Corporation | $90.91 | 2022-2025 | |
| Taiho Oncology, INC. | $75.02 | 2024-2025 | |
| Springworks Therapeutics, INC. | $68.06 | 2025 | Ogsiveo |
| Beone Medicines USA, INC. | $64.28 | 2025 | Tevimbra, Brukinsa |
| Tempus Ai, INC | $62.50 | 2025 | Xt Cdx |
| Array Biopharma INC | $59.59 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Recordati_rare_diseases_inc. | $57.51 | 2023-2025 | Sylvant, Enjaymo |
| Exelixis INC. | $56.23 | 2023-2025 | Cabometyx |
| Lilly USA, LLC | $43.67 | 2024-2025 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $43.05 | 2024-2025 | Zoladex |
| Servier Pharmaceuticals LLC | $41.77 | 2024-2025 | |
| Kyowa Kirin, INC. | $40.78 | 2025 | |
| Astellas Pharma US INC | $40.62 | 2025 | Vyloy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.62 | 2024-2025 | Gilotrif |
| Geron Corporation | $30.55 | 2025 | Rytelo |
| Csl Behring | $30.15 | 2020-2021 | |
| Sobi, INC | $29.06 | 2025 | |
| Incyte Corporation | $24.37 | 2025 | Zynyz, Monjuvi |
| Genmab U.S., INC. | $21.76 | 2025 | Epkinly |
| Beigene USA, INC. | $21.53 | 2025 | Tevimbra |
| Aveo Pharmaceuticals, INC. | $19.87 | 2025 | |
| Stemline Therapeutics INC. | $18.99 | 2025 | Orserdu |
| Seagen INC. | $18.80 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.03 | 2024 | |
| Coherus Oncology, INC. | $17.22 | 2024 | |
| Rigel Pharmaceuticals, INC. | $17.01 | 2023 | Rezlidhia, Tavalisse |
| Novocure INC. | $16.51 | 2025 | Optune Lua (Novottf-200t) |
| Actelion Pharmaceuticals US, INC. | $13.91 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.44 | 2024 | |
| Lupin INC. | $12.68 | 2019 | |
| Dova Pharmaceuticals | $12.66 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Rajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.